Tyndall National Institute, Ireland.
SpectraCure AB, Sweden.
J Biomed Opt. 2021 Jul;26(7). doi: 10.1117/1.JBO.26.7.070604.
Despite remarkable advances in the core modalities used in combating cancer, malignant diseases remain the second largest cause of death globally. Interstitial photodynamic therapy (IPDT) has emerged as an alternative approach for the treatment of solid tumors.
The aim of our study is to outline the advancements in IPDT in recent years and provide our vision for the inclusion of IPDT in standard-of-care (SoC) treatment guidelines of specific malignant diseases.
First, the SoC treatment for solid tumors is described, and the attractive properties of IPDT are presented. Second, the application of IPDT for selected types of tumors is discussed. Finally, future opportunities are considered.
Strong research efforts in academic, clinical, and industrial settings have led to significant improvements in the current implementation of IPDT, and these studies have demonstrated the unique advantages of this modality for the treatment of solid tumors. It is envisioned that further randomized prospective clinical trials and treatment optimization will enable a wide acceptance of IPDT in the clinical community and inclusion in SoC guidelines for well-defined clinical indications.
The minimally invasive nature of this treatment modality combined with the relatively mild side effects makes IPDT a compelling alternative option for treatment in a number of clinical applications. The adaptability of this technique provides many opportunities to both optimize and personalize the treatment.
尽管在癌症治疗的核心手段方面取得了显著进展,但恶性疾病仍然是全球第二大死亡原因。间质光动力疗法 (IPDT) 已成为治疗实体瘤的一种替代方法。
我们的研究旨在概述近年来 IPDT 的进展,并为将其纳入特定恶性疾病标准治疗 (SoC) 指南提供我们的设想。
首先描述了实体瘤的 SoC 治疗方法,并介绍了 IPDT 的诱人特性。其次,讨论了 IPDT 在选定类型肿瘤中的应用。最后,考虑了未来的机会。
学术、临床和工业环境中的大力研究努力导致 IPDT 的当前实施有了重大改进,这些研究证明了这种方式治疗实体瘤的独特优势。预计进一步的随机前瞻性临床试验和治疗优化将使临床界广泛接受 IPDT,并将其纳入针对明确临床适应症的 SoC 指南。
这种治疗方式的微创性质以及相对较轻的副作用使 IPDT 成为许多临床应用中极具吸引力的治疗选择。该技术的适应性为治疗的优化和个性化提供了许多机会。